Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial

• Stated willingness to comply with all study procedures and availability for the duration of the study period

• ≥ 2 years of age

• History of JIA or CAU diagnosed prior to 16 years of age (patient may be older than 16 at time of enrollment)

• Formal diagnosis of JIA-associated uveitis or CAU with no other suspected etiology

• ≥12 consecutive months of controlled ocular inflammation (≤0.5+ anterior chamber cell, ≤0.5+ vitreous haze, no active retinal/choroidal lesions in either eye)

• ≥ 12 consecutive months of controlled arthritis verified by a pediatric rheumatologist, if defined as JIA-associated uveitis

• ≥12 consecutive months of treatment with adalimumab or a biosimilar of adalimumab

• ≥180 days on a stable dose of adalimumab or a biosimilar; must be biweekly dose of either 20mg (if\<30kg) or 40mg (if ≥30kg)

• If on a biosimilar of adalimumab, ≥90 days on the biosimilar

• If on concomitant antimetabolite (injectable or oral methotrexate, mycophenolate mofetil, azathioprine, or leflunomide), dose must be ≤25 mg weekly for methotrexate, ≤3 g daily for mycophenolate mofetil, ≤250 mg daily for azathioprine, or ≤20 mg daily for leflunomide; dose and route of administration must be stable for ≥90 days

• If on topical corticosteroids, dose must be ≤2 drops prednisolone acetate 1% or equivalent per day and stable for ≥90 days

• Willingness to limit consumption of alcohol during the study period

• Agreement to avoid live attenuated vaccinations

• Agreement to use highly effective contraception for ≥28 days prior to screening and throughout study period (for males and females of reproductive age)

• Suitable, in the opinion of the Investigator, to continue treatment with adalimumab or placebo per regional labeling

• No contraindications to receive adalimumab as per the local Summary of Product Characteristics (SmPC)